PeptideStack
5.2kquestions
20kanswers
220users

How should a combination trial be read when both components are active?

Asked 18 Feb 2025Modified 17 months agoViewed 8.4k times
27

I am asking mechanistically rather than practically — I want the model, not the protocol.

This is presented as though it settles something, and I am not convinced it does.

I have two documents that appear to disagree, which is what prompted this.

Which parts of this are informative and which are decoration?

cagrisema
cagrisema

A fixed-ratio combination of cagrilintide, a long-acting amylin analogue, with semaglutide, studied in the REDEFINE programme. Questions here…

8 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
amylin
amylin

Amylin and its analogues, most prominently cagrilintide, as a satiety mechanism orthogonal to incretin signalling. Includes the pharmacology of…

237 questions
shareeditfollowflag
OB
askedotto_brenner12k1618 Feb 2025

No answers yet

This question has not been answered. It has been viewed 8.4k times, which suggests the question is of interest and the answer is not obvious. If you can answer it with a source or a worked calculation, it will be read. See how to ask and answer.
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.